The p53 signal transduction pathway is intact in human neuroblastoma despite cytoplasmic localization

American Journal of Pathology

Volumn 148, Issue 5, 1996, Pages 1381-1385

  Goldman, Stanton C ^a   Chen, Chaw Yaun ^a   Lansing, Timothy J ^b   Gilmer, Tona M ^b   Kastan, Michael B ^a,c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b GLAXOSMITHKLINE   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ARTICLE; CELLULAR DISTRIBUTION; DNA BINDING; DNA DAMAGE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IRRADIATION; NEUROBLASTOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

BLOTTING, WESTERN; CELL CYCLE; CELL FRACTIONATION; CELL NUCLEUS; CYTOPLASM; DNA DAMAGE; DNA, NEOPLASM; GENES, P53; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; NEUROBLASTOMA; POINT MUTATION; POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029868075     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991, 253 49-53
2. Kastan MB, Canman CE, Leonard CJ P53, cell cycle control, and apoptosis: implications for cancer. Cancer Metastasis Rev 1995, 14 3-15
3. Okamoto K, Beach D: Cyclin G is a transcriptional target of the p53 tumor suppressor protein EMBO J 1994, 13.4816-4822
4. Kuerbitz SJ, Plunkett BS, Walsh WV, and Kastan MB: Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 1992, 89.7491-7495
5. Symonds H, Krall L, Remington L, Saenz-Robles M, Lowe S, Jacks T, and Dyke TV. p53- dependent apoptosis suppresses tumor growth and progression in vivo. Cell 1994, 78.703-711
6. Kastan MB, Radin AI, Keurbitz SJ, Onyinye O, Wolkow CA, Civin CI, Stone KD, Woo T, Ravindranith Y, and Craig RW: Levels of p53 protein increase with maturation in human hematopoietic cells. Cancer Res 1991, 52 4279-4286
7. Vogan K, Bernstein M, Leclerc J-M, Brisson L, Brossard J, Brodeur GM, Pelletier J, and Gros P Absence of p53 mutations in primary neuroblastomas. Cancer Res 1993, 53.5269-5273
8. Komuro H, Yasuhide H, Kawamura M, Hayashi K, Kaneko Y, Kamoshita S, Hanada R, Yamamoto K, Hongo T, Yamada M, and Tsuchida Y. Mutations in the p53 gene are involved in Ewing's sarcoma but not in neuroblastomas Cancer Res 1993, 53:5284-5288
9. Castresana JS, Bello MJ, Rey JA, Nebreda P, Queizan A, Garcia-Miguel P, and Pestana A. No tp53 mutations in neuroblastomas detected by PCR-SSCP analysis. Genes Chromosomes Cancer 1994, 10:136-138
10. Hosoi G, Hara J, Okamuru T, Osugi Y, Ishihara S, Fukuzawa M, Okada A, Okada S, and Tawa A: Low frequency of the p53 gene mutations in neuroblastoma Cancer 1994, 73:3087-3093
11. Moll UM, LaQuaglia M, Benard J, and Riou G: Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors Proc Natl Acad Sci USA 1995, 92.4407-4411
12. Canman CE, Wolff, AC, Chen C-Y, Fornace AJ, Kastan MB: The p53-dependent G1 cell cycle check-point and ataxia-telangiectasia Cancer Res 1994, 54:5054-5058
13. Craig RW, Buchan HL, Civin CI, Kastan MB Altered cytoplasmic/nuclear distribution of the c-myc protein in differentiating ML-1 human myeloid leukemia cells. Cell Growth Differ 1993, 4 349-357
14. Moll UM, Riou G, Levine AJ. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci USA 1992, 89 7262-7626